yingweiwo

Apoptosis

Apoptosis

Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.

There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.

Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.

Apoptosis related products

Structure Cat No. Product Name CAS No. Product Description
Pipermethystine V54910 Pipermethystine 71627-22-0 Pipermethystine is an alkaloid extracted from the Kava plant.
Pipernonaline V54869 Pipernonaline 88660-10-0 Pipernonaline is a piperine analogue with antiprostate cancer activity.
Pitavastatin-d4 (NK-104 d4) V54811 Pitavastatin-d4 (NK-104 d4) 2070009-71-9 Pitavastatin-d4 is the deuterium labelled form of Pitavastatin.
Pitstop 2 V40997 Pitstop 2 1419320-73-2 Pitstop 2 is a clathrin inhibitor that can suppress clathrin-mediated endocytosis (CME) by associating with the terminal domain of clathrin.
PK095 V54975 PK095 380314-37-4 PK095 is a p53 mutant stabilizer.
PND-1186 hydrochloride (VS-4718 hydrochloride; SR-2516 hydrochloride) V34731 PND-1186 hydrochloride (VS-4718 hydrochloride; SR-2516 hydrochloride) 1356154-94-3 PND-1186 HCl (VS-4718 HCl) is a potent, specific, reversible FAK inhibitor (antagonist) with IC50 of 1.5 nM.
Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) V35006 Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) 31852-29-6 Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of TLR3 and retinoic acid-inducible gene I receptors (RIG-I and MDA5).
Pomalidomide-d3 (CC-4047-d3) V56427 Pomalidomide-d3 (CC-4047-d3) 2093128-28-8 Pomalidomide-d3 is the deuterated form of Pomalidomide.
POMHEX V40991 POMHEX 2004714-34-3 POMHEX is a racemic mixture (racemate), an active POM precursor molecule of cell-permeable (penetrable) HEX, and a specific inhibitor of ENO2.
Pomstafib-2 V40987 Pomstafib-2 2332841-83-3 Pomstafib-2 is a potent and specific STAT5b inhibitor.
PRDX3(103-112) SO3 modified, human V85939 PRDX3(103-112) SO3 modified, human 847447-04-5
PRDX3(103-112), human V86002 PRDX3(103-112), human 847447-01-2
Prexasertib dimesylate (LY2606368 dimesylate) V40980 Prexasertib dimesylate (LY2606368 dimesylate) 1234015-58-7 Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive, second-generation cell cycle checkpoint kinase 1 (CHK1) inhibitor (antagonist) with a Ki of 0.9 nM and IC50 of <1 nM.
Propylparaben sodium (羟苯丙酯钠; Propyl parahydroxybenzoate sodium; Propyl 4-hydroxybenzoate sodium) V53670 Propylparaben sodium (propyl parahydroxybenzoate sodium; Propyl 4-hydroxybenzoate sodium) 35285-69-9 Propylparaben sodium (Propyl parahydroxybenzoate sodium) is an antimicrobial preservative produced by plants and bacteria.
Propylparaben-d4 (尼泊金丙酯-d4; Propyl parahydroxybenzoate-d4; Propyl 4-hydroxybenzoate-d4) V56243 Propylparaben-d4 (propyl parahydroxybenzoate-d4; Propyl parahydroxybenzoate-d4; Propyl 4-hydroxybenzoate-d4) 1219802-67-1 Propylparaben-d4 is the deuterated form of Propylparaben.
Prostaglandin A2 (PGA2; Medullin) V54809 Prostaglandin A2 (PGA2; Medullin) 13345-50-1 Prostaglandin A2 (PGA2), the endogenously produced metabolite of PGE2 in humans, is an antineoplastic/anticancer agent.
PROTAC Bcl-xL degrader-3 V54921 PROTAC Bcl-xL degrader-3 2471970-60-0 PROTAC Bcl-xL degrader-3 is an effective PROTAC Bcl-xL degrader (For more details, check and find WO2020163823A2, compound 2).
PROTAC Bcl2 degrader-1 V52909 PROTAC Bcl2 degrader-1 2378801-85-3 PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which is effective and specific by introducing pomalidomide, the ligand of E3 ligase cereblon, into the Mcl-1/Bcl-2 dual (bifunctional) inhibitor Nap-1.
PROTAC BRD4 Degrader-16 V40978 PROTAC BRD4 Degrader-16 2585561-36-8 PROTAC BRD4 Degrader-16 is a potent PROTAC BRD4 degrader with IC50s of 34.58 nM (BRD4 (BD1)) and 40.23 nM (BRD4 (BD2)).
PROTAC BRD4 Degrader-17 V40977 PROTAC BRD4 Degrader-17 2585561-49-3 PROTAC BRD4 Degrader-17 (compound 13i) is a potent PROTAC BRD4 degrader with IC50s of 29.54 nM (BRD4 (BD1)) and 3.82 nM (BRD4 (BD2)).
Contact Us